BidaskClub downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a sell rating to a strong sell rating in a report released on Tuesday, September 18th.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald lowered their price target on shares of Collegium Pharmaceutical from $40.00 to $35.00 and set an overweight rating on the stock in a research note on Thursday, August 9th. ValuEngine lowered shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research report on Tuesday, July 10th. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Tuesday, July 10th. Janney Montgomery Scott set a $27.00 price objective on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research report on Monday, August 6th. Finally, Piper Jaffray Companies set a $34.00 target price on shares of Collegium Pharmaceutical and gave the company a buy rating in a report on Wednesday, July 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Collegium Pharmaceutical presently has a consensus rating of Buy and an average price target of $31.71.

COLL traded down $0.07 during trading on Tuesday, hitting $16.95. The stock had a trading volume of 311,040 shares, compared to its average volume of 527,767. The company has a debt-to-equity ratio of 3.94, a quick ratio of 0.78 and a current ratio of 0.82. The stock has a market capitalization of $489.69 million, a P/E ratio of -6.86 and a beta of 0.43. Collegium Pharmaceutical has a twelve month low of $9.01 and a twelve month high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The company had revenue of $73.10 million for the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical’s quarterly revenue was up 1930.6% compared to the same quarter last year. Sell-side analysts predict that Collegium Pharmaceutical will post -1.49 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Investments LLC acquired a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $201,000. Cubist Systematic Strategies LLC acquired a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $213,000. EagleClaw Capital Managment LLC acquired a new stake in Collegium Pharmaceutical in the first quarter valued at approximately $220,000. Stifel Financial Corp acquired a new stake in Collegium Pharmaceutical in the first quarter valued at approximately $224,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Collegium Pharmaceutical in the first quarter valued at approximately $260,000. 93.57% of the stock is owned by hedge funds and other institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: What strategies should day traders use to execute a trade?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.